Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review.
In Cancer treatment reviews
By: Gupta K.
Contributor(s): Charbonneau C | Russel MW | Li JZ | Miller JD | Mason_Russell@abtassoc.com.
Material type:
ArticleSeries: Vol 34 Issues 3.Publisher: 2008Description: 193-205.Subject(s): Sunitinib | Sorafenib | economics | Cost | Quality of Life | Prevalence | Incidence | Epidemiology | Burden | Metastatic renal cell carcinoma | DDC classification:
In:
Cancer treatment reviewsSummary: Renal cell carcinoma (RCC), the most common form of kidney cancer, initially has an asymptomatic clinical course; 25-30% of patients present with metastatic disease at time of diagnosis. Worldwide incidence and mortality rates are rising at a rate of approximately 2-3% per decade. Metastatic RCC (mRCC) is one of the most treatment-resistant malignancies; outcomes are generally poor and median survival after diagnosis is less than one year. Surgery and chemotherapy have limited or no effect, leaving mRCC patients underserved in the realm of cancer treatment. As the world's population ages and the prevalence of risk factors (obesity, hypertension) increases, the burden of mRCC is predicted to increase significantly. With a shift in treatment of mRCC to novel therapies, such as molecularly targeted therapies (MTTs) (e.g., sorafenib and sunitinib), clinicians, payers, and other healthcare decision-makers must re-evaluate the optimal role for new treatments. Timely understanding of the burden of mRCC on individu
| Item type | Current location | Call number | Status | Date due | Barcode |
|---|---|---|---|---|---|
Articles
|
Tata Memorial Hospital | Available | AR8093 |
Renal cell carcinoma (RCC), the most common form of kidney cancer, initially has an asymptomatic clinical course; 25-30% of patients present with metastatic disease at time of diagnosis. Worldwide incidence and mortality rates are rising at a rate of approximately 2-3% per decade. Metastatic RCC (mRCC) is one of the most treatment-resistant malignancies; outcomes are generally poor and median survival after diagnosis is less than one year. Surgery and chemotherapy have limited or no effect, leaving mRCC patients underserved in the realm of cancer treatment. As the world's population ages and the prevalence of risk factors (obesity, hypertension) increases, the burden of mRCC is predicted to increase significantly. With a shift in treatment of mRCC to novel therapies, such as molecularly targeted therapies (MTTs) (e.g., sorafenib and sunitinib), clinicians, payers, and other healthcare decision-makers must re-evaluate the optimal role for new treatments. Timely understanding of the burden of mRCC on individu
There are no comments for this item.